Eagle Pharmaceuticals Price to Free Cash Flow Ratio 2013-2023 | EGRX

Eagle Pharmaceuticals price to free cash flow ratio from 2013 to 2023. Price to free cash flow ratio can be defined as

Eagle Pharmaceuticals Price to Free Cash Flow Ratio 2013-2023 | EGRX

Eagle Pharmaceuticals price to free cash flow ratio from 2013 to 2023. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$196.7B
Stryker (SYK)$142.8B
Boston Scientific (BSX)$132.8B
EssilorLuxottica (ESLOY)$110.9B
Medtronic (MDT)$105.8B
Haleon (HLN)$44.2B
Lonza Group Ag (LZAGY)$43.1B
GE HealthCare Technologies (GEHC)$37.1B
ResMed (RMD)$35B
Terumo (TRUMY)$29.6B
Koninklijke Philips (PHG)$24.2B
Zimmer Biomet Holdings (ZBH)$21.2B
Insulet (PODD)$18.9B
Baxter (BAX)$15.5B
Smith & Nephew SNATS (SNN)$11.2B
BellRing Brands (BRBR)$10B
Bio-Rad Laboratories (BIO)$9.4B
Demant (WILYY)$8.3B
Lantheus Holdings (LNTH)$6.5B
Haemonetics (HAE)$4.1B
Prestige Consumer Healthcare (PBH)$4.1B
ICU Medical (ICUI)$4B
Perrigo (PRGO)$3.7B
Envista Holdings (NVST)$3.4B
Shandong Weigao Medical Polymer (SHWGF)$3B
GN Store Nord (GNNDY)$2.9B
QuidelOrtho (QDEL)$2.8B
Neogen (NEOG)$2.6B
LeMaitre Vascular (LMAT)$2.3B
Green Thumb Industries (GTBIF)$1.7B